within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02A_Uterotonics.G02AB01_Methylergometrine;

model Methylergometrine_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 5.0555555555555555e-06,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.0008399999999999999,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Methylergometrine_1</td></tr><tr><td>ATC code:</td><td>G02AB01_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.84</td><td>L</td></tr>
    <tr><td>clearance:</td><td>18.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Methylergometrine (methylergometrine maleate or methylergonovine) is a semisynthetic ergot alkaloid used primarily to prevent or control excessive bleeding after childbirth (postpartum hemorrhage) due to its uterotonic properties. It is approved for medical use and remains in use today in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy postpartum women following intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G02AB01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Methylergometrine_1;
